U.S. Court rules Merck's Zetia patent valid
(Reuters) - A U.S. court on Friday ruled that the patent on Merck & Co's (MRK.N: Quote) cholesterol fighter Zetia and a related drug Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc (MYL.O: Quote) until the patent expires.
Mylan had admitted that its product would infringe the patent, which run until April of 2017, Merck said.
Merck earlier on Friday said first-quarter sales of Zetia, known chemically as ezetimibe, rose 6 percent to $614 million, while Vytorin, which combines Zetia with Merck's older cholesterol drug Zocor, saw sales slip 8 percent to $444 million.
In a ruling in U.S. District court for the district of New Jersey, Judge Jose Linares declared the patent to be "valid and enforceable."
(Reporting By Bill Berkrot)
© Thomson Reuters 2015 All rights reserved.